|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, FRα CAR T cells induced superior tumor regression in vivo against MDA-MB-231 that was engineered for overexpression of FRα.
|
27439908 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FOLR1 targeting resulted in disassembly of the porphysomes and subsequent fluorescence activation in intrathoracic disseminated MPM tumors, as demonstrated by ex vivo tissue imaging.
|
30226590 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pituitary adenomas are known to overexpress folate receptor alpha (FRα), and it was hypothesized that OTL38, a folate analog conjugated to a near-infrared (NIR) fluorescent dye, could provide real-time intraoperative visual contrast of the tumor versus the surrounding nonneoplastic tissues.
|
28841122 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results show that anti-FRα CAR outfitted with CD137 costimulatory signaling in tandem overcome issues of T-cell persistence and tumor localization that limit the conventional FRα T-cell targeting strategy to provide potent antitumor activity in vivo.
|
21546571 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Glycine N-methyltransferase (GNMT) is a folate binding protein commonly diminished in human hepatoma yet its role in tumor development remains to be established.
|
23922098 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Xenografts of NaAsIII‑preconditioned MCF7 cells (MCF7NaAsIII) into the mammary fat pads of nude mice produced a larger tumor volume compared to tumors from control MCF7 cells and were more refractory to TAM in association with the reduced expression of BRCA1 and ERα, CpG hypermethylation of estrogen receptor 1 (ESR1) and BRCA1, and the increased expression of FOLR1.
|
30664189 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FLT3 receptor (FR) gene was not expressed and exogenous addition to the cultures of recombinant FL (rFL) did not affect the proliferation of the tumor lines.
|
10738251 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid.
|
29129656 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Folate receptor alpha as a tumor target in epithelial ovarian cancer.
|
18222534 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using quantitative PCR, both mesothelin (MSLN) and PTGS1 (COX1) were significantly increased in FOLR1 overexpressing tumors (p=0.014 and p=0.006 respectively).
|
17400285 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, MOv18-IgG1 triggered immune-dependent cancer cell death <i>in vitro</i> by human volunteer and breast cancer patient immune cells, and significantly restricted orthotopic and patient-derived xenograft growth.<b>Conclusions:</b> FRα is overexpressed in high-grade TNBC and postchemotherapy residual tumors.
|
30068707 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This highly tumor restricted expression profile makes FRα a promising target for tumor therapy and diagnosis.
|
29849110 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Folr1 targeted therapy attenuated the tumor growth and metastasis with down-regulation of MMPs proteins and activation of apoptosis.
|
28416738 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Downregulation of FRα and CLDN3 in ovarian cancer may suppress tumor growth and promote benign differentiation of tumor.
|
24144916 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the protective model, in which C57BL/6 mice were immunized with the FRα DNA vaccine four weeks before tumor cell inoculation, the growth of tumor was significantly inhibited, and the presence of CpG ODN further increased the inhibitory effect.
|
28498413 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Farletuzumab is a monoclonal antibody targeting FOLR1 which in pre-clinical studies led to cytotoxicity of FOLR1-expressing cells, inhibited tumor growth in animal models and showed limited reactivity with normal tissue.
|
23357463 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analysis of FRalpha expression by Western blotting confirmed that FRalpha protein was specifically overexpressed in NF tumors.
|
12874029 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
|
31679978 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FRα expression in tumors was determined immunohistochemically.
|
28826214 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumors from never-smokers were more likely to express cytoplasmic (OR = 3.35; p<0.03) and membrane (OR = 3.60; p=0.0005) FRα than those from smokers.
|
22729036 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Exposure to FRα-expressing ovarian tumour cells at target-to-effector ratios expected within tumours induced degranulation.
|
21569129 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results did not show any association between the RFC and FRα protein expression and tumor stage, TNM classification, or tumor location.
|
25697897 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FOLR1 and FPGS associated with tumor differentiation (both p<0.0001), spread to regional lymph nodes (FOLR1 p=0.0001 and FPGS p=0.0038), OS and PFS (FOLR1 p<0.0050 for both and FPGS p<0.0004 for OS).
|
27064343 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immune monitoring posttreatment showed an increase in effector T cells recognizing the tumor antigens IGFBP2 and FRα, indicating that MV-NIS treatment triggered cellular immunity against the patients' tumor and suggesting that an immune mechanism mediating the observed antitumor effect.
|
25398436 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate that through chemically programmed specificity for integrin α(4)β(1) or folate receptor 1 (FOLR1), and common specificity for CD3, these hybrid molecules exert potent and specific in vitro and ex vivo cytotoxicity toward tumor cell lines and primary tumor cells in the presence of primary T cells.
|
22761439 |
2012 |